InVivoMAb anti-LCMV nucleoprotein

Herz J, Johnson KR, McGavern DB. Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells. J Exp Med. 2015,212(8):1153-69. doi: 10.1084/jem.20142047

Ng CT, Sullivan BM, Teijaro JR, et al. Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe. 2015,17(5):653-61. doi: 10.1016/j.chom.2015.04.005

Pritzl CJ, Seo YJ, Xia C, et al. A ceramide analogue stimulates dendritic cells to promote T cell responses upon virus infections. J Immunol. 2015,194(9):4339-49. doi: 10.4049/jimmunol.1402672

Sullivan BM, Teijaro JR, de la Torre JC, et al. Early virus-host interactions dictate the course of a persistent infection. PLoS Pathog. 2015,11(1):e1004588. doi: 10.1371/journal.ppat.1004588

Beura LK, Anderson KG, Schenkel JM, et al. Lymphocytic choriomeningitis virus persistence promotes effector-like memory differentiation and enhances mucosal T cell distribution. J Leukoc Biol. 2015,97(2):217-25. doi: 10.1189/jlb.1HI0314-154R

Seo YJ, Hahm B. Sphingosine analog AAL-R promotes activation of LCMV-infected dendritic cells. Viral Immunol. 2014,27(2):82-6. doi: 10.1089/vim.2013.0096

Nayak D, Johnson KR, Heydari S, et al. Type I interferon programs innate myeloid dynamics and gene expression in the virally infected nervous system. PLoS Pathog. 2013,9(5):e1003395. doi: 10.1371/journal.ppat.1003395